vs
Side-by-side financial comparison of Cue Biopharma, Inc. (CUE) and NATIONAL BANKSHARES INC (NKSH). Click either name above to swap in a different company.
Cue Biopharma, Inc. is the larger business by last-quarter revenue ($21.9M vs $15.3M, roughly 1.4× NATIONAL BANKSHARES INC). NATIONAL BANKSHARES INC runs the higher net margin — 38.5% vs 7.2%, a 31.3% gap on every dollar of revenue. On growth, Cue Biopharma, Inc. posted the faster year-over-year revenue change (1292.3% vs 24.7%). Over the past eight quarters, Cue Biopharma, Inc.'s revenue compounded faster (257.5% CAGR vs 20.9%).
Cue Biopharma is a clinical-stage biotechnology company focused on developing novel targeted immunotherapies for cancer, autoimmune disorders, and inflammatory diseases. Its proprietary platform enables precise T-cell activity modulation, with core operations in North America and global pharma partnerships to advance lead product candidates through clinical trials.
Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.
CUE vs NKSH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.9M | $15.3M |
| Net Profit | $1.6M | $5.9M |
| Gross Margin | — | — |
| Operating Margin | 9.0% | 47.4% |
| Net Margin | 7.2% | 38.5% |
| Revenue YoY | 1292.3% | 24.7% |
| Net Profit YoY | 116.7% | 91.0% |
| EPS (diluted) | $0.05 | $0.93 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.9M | $15.3M | ||
| Q3 25 | $2.1M | $14.2M | ||
| Q2 25 | $3.0M | $13.3M | ||
| Q1 25 | $421.0K | $12.8M | ||
| Q4 24 | $1.6M | $12.2M | ||
| Q3 24 | $3.3M | $11.7M | ||
| Q2 24 | $2.7M | $10.9M | ||
| Q1 24 | $1.7M | $10.4M |
| Q4 25 | $1.6M | $5.9M | ||
| Q3 25 | $-7.4M | $4.4M | ||
| Q2 25 | $-8.5M | $2.3M | ||
| Q1 25 | $-12.3M | $3.2M | ||
| Q4 24 | — | $3.1M | ||
| Q3 24 | $-8.7M | $2.7M | ||
| Q2 24 | $-10.2M | $-307.0K | ||
| Q1 24 | $-12.3M | $2.2M |
| Q4 25 | 9.0% | 47.4% | ||
| Q3 25 | -353.4% | 37.9% | ||
| Q2 25 | -292.3% | 20.0% | ||
| Q1 25 | -2921.4% | 30.5% | ||
| Q4 24 | — | 30.1% | ||
| Q3 24 | -264.2% | 27.5% | ||
| Q2 24 | -390.6% | -4.4% | ||
| Q1 24 | -737.8% | 25.8% |
| Q4 25 | 7.2% | 38.5% | ||
| Q3 25 | -346.6% | 31.1% | ||
| Q2 25 | -287.1% | 17.2% | ||
| Q1 25 | -2911.4% | 25.3% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | -259.6% | 22.8% | ||
| Q2 24 | -382.7% | -2.8% | ||
| Q1 24 | -719.1% | 20.8% |
| Q4 25 | $0.05 | $0.93 | ||
| Q3 25 | $-0.07 | $0.69 | ||
| Q2 25 | $-0.09 | $0.36 | ||
| Q1 25 | $-0.17 | $0.51 | ||
| Q4 24 | — | $0.50 | ||
| Q3 24 | $-0.17 | $0.42 | ||
| Q2 24 | $-0.20 | $-0.05 | ||
| Q1 24 | $-0.25 | $0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.1M | $59.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.4M | $184.9M |
| Total Assets | $42.2M | $1.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.1M | $59.3M | ||
| Q3 25 | $11.7M | $42.3M | ||
| Q2 25 | $27.5M | $92.8M | ||
| Q1 25 | $13.1M | $122.5M | ||
| Q4 24 | $22.5M | $108.1M | ||
| Q3 24 | $32.4M | $49.8M | ||
| Q2 24 | $30.0M | $98.9M | ||
| Q1 24 | $41.0M | $121.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
| Q4 25 | $26.4M | $184.9M | ||
| Q3 25 | $13.2M | $179.2M | ||
| Q2 25 | $18.2M | $168.7M | ||
| Q1 25 | $6.6M | $167.3M | ||
| Q4 24 | $17.5M | $156.4M | ||
| Q3 24 | $25.4M | $167.8M | ||
| Q2 24 | $21.6M | $149.0M | ||
| Q1 24 | $30.0M | $139.4M |
| Q4 25 | $42.2M | $1.8B | ||
| Q3 25 | $31.6M | $1.8B | ||
| Q2 25 | $40.7M | $1.8B | ||
| Q1 25 | $22.3M | $1.8B | ||
| Q4 24 | $32.2M | $1.8B | ||
| Q3 24 | $44.8M | $1.8B | ||
| Q2 24 | $42.3M | $1.8B | ||
| Q1 24 | $54.0M | $1.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | $17.9M |
| Free Cash FlowOCF − Capex | — | $15.2M |
| FCF MarginFCF / Revenue | — | 99.2% |
| Capex IntensityCapex / Revenue | 0.0% | 17.9% |
| Cash ConversionOCF / Net Profit | -0.68× | 3.04× |
| TTM Free Cash FlowTrailing 4 quarters | — | $23.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.1M | $17.9M | ||
| Q3 25 | $-9.0M | $6.1M | ||
| Q2 25 | $-3.4M | $2.1M | ||
| Q1 25 | $-8.2M | $2.6M | ||
| Q4 24 | $-36.3M | $9.4M | ||
| Q3 24 | $-7.5M | $3.1M | ||
| Q2 24 | $-10.0M | $-3.0M | ||
| Q1 24 | $-9.8M | $3.8M |
| Q4 25 | — | $15.2M | ||
| Q3 25 | — | $5.3M | ||
| Q2 25 | $-3.4M | $1.5M | ||
| Q1 25 | $-8.3M | $1.6M | ||
| Q4 24 | $-36.4M | $6.2M | ||
| Q3 24 | $-7.5M | $2.2M | ||
| Q2 24 | $-10.0M | $-4.0M | ||
| Q1 24 | $-9.8M | $3.5M |
| Q4 25 | — | 99.2% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | -116.5% | 11.5% | ||
| Q1 25 | -1976.7% | 12.5% | ||
| Q4 24 | -2309.3% | 50.5% | ||
| Q3 24 | -225.7% | 18.5% | ||
| Q2 24 | -376.2% | -36.3% | ||
| Q1 24 | -573.0% | 33.8% |
| Q4 25 | 0.0% | 17.9% | ||
| Q3 25 | 0.0% | 5.6% | ||
| Q2 25 | 0.9% | 4.1% | ||
| Q1 25 | 35.6% | 7.5% | ||
| Q4 24 | 4.2% | 26.6% | ||
| Q3 24 | 0.0% | 8.3% | ||
| Q2 24 | 0.4% | 9.3% | ||
| Q1 24 | 3.2% | 3.0% |
| Q4 25 | -0.68× | 3.04× | ||
| Q3 25 | — | 1.38× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.79× | ||
| Q4 24 | — | 3.07× | ||
| Q3 24 | — | 1.17× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.77× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
NKSH
Segment breakdown not available.
